



Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Investor presentation

London, UK, 13 December 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer[®]/Feraccru[®] (ferric maltol), announces that it will provide a live investor presentation on Wednesday 14 December 2022 at 4.30pm (GMT).

Chief Executive Officer, Greg Madison, Chief Financial Officer, Hans-Peter Rudolf and Chief Medical Officer, José Menoyo, will provide an update to investors following the recent collaborative sales agreement and equity raise. Investors can sign up to Investor Meet Company for free and request to meet Shield Therapeutics plc via the following link: <https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor>

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of regulations and information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

For further information please contact:

Shield Therapeutics plc

Greg Madison, CEO
Hans-Peter Rudolf, CFO

www.shieldtherapeutics.com

+44 (0) 191 511 8500

Financial PR & IR Advisor

Walbrook PR

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly

+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer[®]/Feraccru[®]

Accrufer[®]/Feraccru[®] (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer[®]/Feraccru[®] has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer[®]/Feraccru[®], including the product label, can be found at: www.acrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer[®]/Feraccru[®] (ferric maltol). The Group has launched Accrufer[®] in the US and Feraccru[®] is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer[®] / Feraccru[®] in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer[®]/Feraccru[®] has patent coverage until the mid-2030s

Accrufer[®]/Feraccru[®] are registered trademarks of the Shield Group